Mengcui Gui, Jiayang Zhan, Wei Li, Tao Jin, Dan He, Daishi Tian et al. Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study. // Annals of Clinical and Translational Neurology. – 2026. – DOI: 10.1002/acn3.70512. – URL: https://onlinelibrary.wiley.com/doi/10.1002/acn3.70512?af=R
Mengcui Gui, Jiayang Zhan, Wei Li, Tao Jin, Dan He, Daishi Tian, Zhijun Li, Jing Lin, Yue Li, Hongyu Zhou, & Bitao Bu (2026). Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70512
Mengcui Gui, et al. “Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study.” Annals of Clinical and Translational Neurology, 2026. doi:10.1002/acn3.70512.
@article{Gui2026,
title = {Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study},
author = {Gui, Mengcui and Zhan, Jiayang and Li, Wei and Jin, Tao and He, Dan and Tian, Daishi and Li, Zhijun and Lin, Jing and Li, Yue and Zhou, Hongyu and Bu, Bitao},
journal = {Annals of Clinical and Translational Neurology},
year = {2026},
doi = {10.1002/acn3.70512},
url = {https://onlinelibrary.wiley.com/doi/10.1002/acn3.70512?af=R}
}